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This study sought to compare clinical outcomes between bioresorbable scaffolds (BRS) and
durable polymer everolimus-eluting metallic stents (DP-EES) in patients with acute myocar-
dial infarction (AMI) undergoing successful percutaneous coronary intervention (PCI).
Methods
From March 2016 to October 2017, 952 patients with AMI without cardiogenic shock under-
going successful PCI with BRS (n = 136) or DP-EES (n = 816) were enrolled from a multi-
center, observational Korea Acute Myocardial Infarction Registry.
Results
In the crude population, there was no significant difference in the 1-year rate of device-ori-
ented composite endpoint (DOCE) and device thrombosis between the BRS and DP-EES
groups (2.2% vs. 4.8%, hazard ratio [HR] 0.43, 95% confidence interval [CI] 0.13–1.41, p =
0.163; 0.7% vs. 0.5%, HR 1.49, 95% CI 0.16–13.4, p = 0.719, respectively). BRS implanta-
tion was opted in younger patients (53.7 vs. 62.6 years, p < 0.001) with low-risk profiles, and
intravascular image-guided PCI was more preferred in the BRS group (60.3% vs. 27.2%, p
< 0.001).
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Conclusions
At 1-year follow-up, no differences in the rate of DOCE and device thrombosis were
observed between patients with AMI treated with BRS and those treated with DP-EES. Our
data suggest that imaging-guided BRS implantation in young patients with low risk profiles
could be a reasonable strategy in the setting of AMI.
Introduction
Percutaneous coronary intervention (PCI) with new-generation metallic drug-eluting stents
(DES), as compared with bare-metal stents (BMS) and first-generation metallic DES, evidently
improved clinical outcomes in patients with ischemic heart disease [1–3]. However, the new-
generation metallic DES may have long-term limitations induced by the permanent presence
of foreign material in the coronary artery [4]. Thus, everolimus-eluting bioresorbable scaffolds
(BRS) such as AbsorbTM (Abbott Vascular, Santa Clara, CA, USA) were designed to overcome
the limitations of metallic DES [5]. In the four major randomized trials regarding BRS versus
durable polymer everolimus-eluting metallic stents (DP-EES) (XIENCE1, Abbott Vascular),
the 1-year clinical outcomes of BRS were comparable with those of DP-EES, although there
were concerns about increased rates of device thrombosis in the BRS group [5–8]. A recent
large-scale randomized trial demonstrated that compared with DP-EES, BRS was associated
with a significantly higher incidence of device thrombosis [9]. Further, an analysis of the seven
randomized trials comparing BRS with metallic DES showed that compared with DP-EES,
BRS had a significantly higher rate of target lesion failure and device thrombosis at the 2-year
follow-up [10]. Finally, current guidelines recommend that BRS should not be used in clinical
practice outside of clinical studies [11]. Nevertheless, the safety of BRS implantation for acute
myocardial infarction (AMI) patients has been demonstrated in two randomized studies; no
significant differences in the incidence of adverse outcomes and device thrombosis were
observed between the BRS and DP-EES groups in these studies [12,13]. However, there is a
lack of data regarding clinical outcomes in AMI patients who undergo BRS implantation in a
real world setting.
Therefore, we sought to compare the clinical outcomes between patients with AMI under-
going successful PCI with BRS and DP-EES, using a nationwide, multicenter registry for AMI.
Material and methods
The study population was selected from the Korea Acute Myocardial Infarction Registry
(KAMIR) database. The KAMIR is the first nationwide, multicenter, observational registry of
patients with AMI in Korea, and it reflects “real-world” treatment practice and outcome in
patients with AMI. AMI was diagnosed when there was an increased level of cardiac-specific
biomarkers, such as troponin I/T or creatinine kinase-MB, with at least one value above the
99th percentile upper reference limit and with at least 1 of the following: symptom of myocar-
dial ischemia, new significant ST-segment-T wave changes, new left bundle branch block, or
pathologic Q waves in two contiguous leads on a 12-lead electrocardiogram, and imaging evi-
dence of new loss of viable myocardium or new regional wall motion abnormality [14].
The study protocol was approved by the ethics committee at each participating center, and
the principles of the Declaration of Helsinki were followed (approval number: CNUH-2016-
075). Written informed consent was obtained from each patient. If patients were unable to
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provide consent at the time of presentation, informed consent was obtained from their relative
or legal representative.
Among the 6,970 patients enrolled in KAMIR between March 2016 and October 2017,
patients who underwent successful PCI with BRS or DP-EES were selected. Patients who pre-
sented with cardiogenic shock or those who were lost to follow-up within the year preceding
the study were excluded. Finally, 952 patients were included in the present study (Fig 1).
The patients were managed as per current standard guidelines. The decision of PCI strat-
egy, including the selection of medication, stent, and vascular access, and use of intravascular
imaging guidance, thrombus aspiration, and glycoprotein IIb/IIIa inhibitor, was left to the dis-
cretion of the operators.
The primary outcome was device-oriented composite endpoint (DOCE) including cardiac
death, target vessel myocardial infarction (TV-MI), and ischemic-driven target lesion revascu-
larization (ID-TLR) at 1 year. The secondary endpoint was patient-oriented composite end-
point (POCE) of all-cause death, all MI, and all revascularization at 1 year. All individual
components and device thrombosis (stent/scaffold), defined by the Academic Research Con-
sortium criteria, were also analyzed [15].
Fig 1. Study flowchart.
https://doi.org/10.1371/journal.pone.0235673.g001
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Statistical analysis
All continuous variables were expressed as the mean and standard deviation (SD) or median
with interquartile ranges (IQR), when appropriate. All categorical variables were reported as
numbers with percentages. The continuous variables were compared using the unpaired t-test
or Mann–Whitney U test, as appropriate. The categorical variables were analyzed using the χ2
test or Fisher’s exact test. Cumulative event rates were calculated based on Kaplan–Meier cen-
soring estimates, and clinical outcomes between the BRS and DP-EES groups were compared
using the log-rank test. As differences in baseline characteristics could significantly affect the
outcomes, sensitivity analyses were performed to adjust for confounders as much as possible.
First, the hazard ratios of the unadjusted and adjusted models were calculated using Cox
proportional hazard models. The following variables were included in multivariate Cox regres-
sion analysis: age�60 years, ST-elevation myocardial infarction (STEMI), hypertension, intra-
vascular image-guided PCI, and multi-vessel disease (MVD). C-statistics with 95% confidence
intervals (CIs) were calculated to validate the discriminant function of the model.
Second, Cox proportional hazard regression in a propensity-score matched cohort was used.
The propensity score was estimated for the choice of BRS using a multivariable logistic regression
model that included 24 covariates including age, sex, current smoking, hypertension, diabetes
mellitus (DM), estimated glomerular filtration rate (eGFR), left ventricular ejection fraction
(LVEF), troponin I, clopidogrel, ticagrelor, angiotensin-converting enzyme inhibitor or angioten-
sion-II receptor blocker, beta-blocker, statin, infarct-related artery, American College of Cardiol-
ogy/American Heart Association B2/C lesion, MVD, vascular access, intravascular image-guided
PCI including intravascular ultrasound (IVUS) and optical coherence tomography (OCT), glyco-
protein IIb/IIIa inhibitor, pre-PCI Thrombolysis in Myocardial Infarction (TIMI) flow grade 0/1,
post-PCI TIMI flow grade 3, mean stent/scaffold diameter, length, and total stent/scaffold num-
ber. Propensity score matching yielded 95 patients in the BRS group and 205 control subjects in
the DP-EES group. The C-statistic of the logistic regression model for propensity score matching
was 0.655. To assess the efficacy of the propensity score model, the standardized differences for
each covariate between the groups were calculated. A close to % absolute standard difference for a
covariate indicated absence of residual bias, whereas a value within 20% indicated inconsequential
residual bias. Balance between the two groups after propensity-score matching was assessed by
calculating percent standardized mean differences. Percent standardized mean differences after
propensity-score matching were within 20% across all matched covariates, demonstrating success-
ful achievement of balance between the groups. We used a univariate and multivariable Cox pro-
portional hazard model to identify the independent predictor of DOCE and POCE.
All analyses were two-tailed, and a p value < 0.05 was considered to reflect significance. All
statistical analyses were performed using R Core Team (2015). R: A language and environment




Among the total patient population, 136 patients underwent PCI with BRS and 816 patients
underwent PCI with DP-EES. The average patient age was 61.3 ± 11.9 years, and 52.8% of the
patients presented with STEMI. Baseline clinical characteristics of the BRS and DP-EES groups
are shown in Table 1. The BRS group comprised younger patients (BRS vs. DP-EES, 53.7 ±
10.4 years vs. 62.6 ± 11.6 years; p< 0.001) and more men. The DP-EES group had a higher
prevalence of hypertension and DM; however, current smoking was more prevalent in the
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BRS group. LVEF was more preserved in the BRS group than in the DP-EES group. With
regard to medication at discharge, all patients in the BRS group received aspirin, but ticagrelor
was more commonly prescribed in this group. In the propensity-matched population, baseline
clinical parameters were well-balanced between the groups.
Table 1. Baseline clinical characteristics of the study population.
Overall patients After propensity-score matching
BRS (n = 136) DP-EES (n = 816) p value BRS (n = 95) DP-EES (n = 205) p value SD (%)
Demographics
Age, years 53.7 ± 10.4 62.6 ± 11.6 <0.001 54.8 ± 10.8 56.2 ± 10.3 0.266 -6.7
Male 123 (90.4) 624 (76.5) <0.001 85 (89.5) 179 (87.3) 0.731 5.94
BMI, kg/m2 24.5 ± 3.0 24.4 ± 3.5 0.801 24.5 ± 3.1 24.3 ± 2.9 0.629 1.2
Vital sign on admission
SBP, mmHg 133.4 ± 26.8 131.5 ± 26.3 0.433 131.8 ± 27.7 133.5 ± 25.6 0.608 -2.45
DBP, mmHg 82.2 ± 18.6 79.3 ± 16.4 0.094 81.0 ± 18.0 82.1 ± 16.3 0.606 -3.67
HR, beat/min 77.2 ± 15.3 78.7 ± 19.2 0.325 77.3 ± 16.0 78.8 ± 18.5 0.471 -0.68
Initial presentation
Diagnosis 0.662 1.000 2.1
STEMI 69 (50.7) 434 (53.2) 45 (47.4) 97 (47.3)
NSTEMI 67 (49.3) 382 (46.8) 50 (52.6) 108 (52.7)
Killip class� III 13 (9.6) 82 (10.0) 0.982 8 (8.4) 16 (7.8) 1.000 1.78
Cardiovascular risk factors
Current smoking 80 (58.8) 344 (42.2) <0.001 51 (53.7) 112 (54.6) 0.977 -0.71
Hypertension 42 (30.9) 390 (47.8) <0.001 31 (32.6) 76 (37.1) 0.537 -7.19
Diabetes mellitus 21 (15.4) 214 (26.2) 0.010 18 (18.9) 46 (22.4) 0.592 -2.9
Dyslipidemia 14 (10.3) 100 (12.3) 0.610 10 (10.5) 18 (8.8) 0.787 6.33
Familial history of IHD 15 (11.0) 79 (9.7) 0.859 8 (8.4) 21 (10.2) 0.774 -0.56
Prior MI 4 (2.9) 24 (2.9) 1.000 2 (2.1) 8 (3.9) 0.645 -9.31
Prior CHF 3 (2.2) 13 (1.6) 0.877 2 (2.1) 7 (3.4) 0.799 -9.52
Prior CVA 2 (1.5) 44 (5.4) 0.079 2 (2.1) 3 (1.5) 1.000 2.9
LVEF, % 55.0 ± 10.3 52.4 ± 10.9 0.010 54.8 ± 10.2 53.0 ± 10.8 0.164 5.85
eGFR, mL/min/1.73 m2 95.8 [80.5–111.8] 83.7 [65.7–104.1] <0.001 94.9 [80.2–109.0] 86.7 [72.5–107.3] 0.148 1.14
Peak cardiac enzyme levels
Peak CK- MB, ng/ml 80 [22.6–241.0] 56.6 [10.0–191.5] 0.074 80 [23.6–234.8] 47.1 [8.8–165] 0.083 -1.99
Troponin I, ng/ml 23 [6.6–30.0] 30 [11.4–40.0] <0.001 23 [8.8–31.9] 30 [5.8–40] 0.148 4.3
Medications at discharge
Aspirin 136 (100.0) 809 (99.1) 0.588 95 (100.0) 203 (99.0) 0.839 0.1
Clopidogrel 36 (26.5) 309 (37.9) 0.014 25 (26.3) 56 (27.3) 0.967 -3.17
Ticagrelor 101 (74.3) 482 (59.1) 0.001 72 (75.8) 150 (73.2) 0.734 4.0
Prasugrel 7 (5.1) 61 (7.5) 0.426 6 (6.3) 11 (5.4) 0.950 0.79
ACEI or ARB 116 (85.3) 607 (74.4) 0.008 78 (82.1) 165 (80.5) 0.862 -0.49
Beta-blocker 116 (85.3) 652 (77.9) 0.175 79 (83.2) 172 (83.9) 1.000 0.49
Statin 135 (99.3) 756 (92.6) 0.006 94 (98.9) 199 (97.1) 0.556 9.32
Oral anticoagulant 2 (1.5) 26 (3.2) 0.411 1 (1.1) 3 (1.5) 1.000 0
Values are mean ± SD, median [interquartile range], or n (%).
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin-II receptor blocker; BMI, body mass index; BRS, bioresorbable scaffolds; CHF, congestive heart
failure; CK-MB, creatine kinase-myocardial band; CVA, cerebrovascular accident; DBP, diastolic blood pressure; DP-EES, durable polymer everolimus-eluting metallic
stents; eGFR, estimated glomerular filtration rate; HR, heart rate; IHD, ischemic heart disease; LVEF, left ventricular ejection fraction; MI, myocardial infarction; SBP,
Systolic blood pressure; STEMI, ST-segment elevation myocardial infarction.
https://doi.org/10.1371/journal.pone.0235673.t001
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Angiographic and procedural characteristics
The angiographic and procedural characteristics of all patients are presented in Table 2. No
patients in the BRS group had the left main coronary artery as the infarct-related artery,
whereas 3.7% of patients in the DP-EES group had the left main coronary artery as the culprit
lesion. Compared with patients from the BRS group, those from the DP-EES group were more
likely to have MVD. The transradial approach, thrombus aspiration, and use of glycoprotein
IIb/IIIa inhibitors were more frequent in the BRS group. Moreover, more patients in the BRS
group underwent intravascular image-guided PCI (BRS vs. DP-EES, 60.3% vs. 27.5%; p<
0.001), especially under OCT guidance (BRS vs. DP-EES, 36.8% vs. 2.5%). Compared with the
DP-EES group, the BRS group showed a larger mean implanted device diameter (BRS vs.
DP-EES, 3.3 ± 0.3 mm vs. 3.2 ± 0.4 mm; p< 0.001), shorter device length (BRS vs. DP-EES,
21.4 ± 4.5 mm vs. 25.1 ± 7.1 mm; p< 0.001), and fewer implanted devices (BRS vs. DP-EES,
1.2 ± 0.6 vs. 1.5 ± 0.8; p< 0.001). After propensity score matching, the angiographic and pro-
cedural characteristics were well-balanced between the groups.
Clinical outcomes according to the device used
In the crude population, there was no significant difference in the 1-year rate of DOCE
between the groups (Fig 2). The risk of POCE was significantly lower in the BRS group than in
the DP-EES group; however, multivariate adjustment and propensity score matching did not
show any difference in the 1-year rate of POCE between the groups (Table 3). There was no
Table 2. Angiographic and procedural characteristics of the study population.
Overall patients After propensity-score matching
BRS (n = 136) DP-EES (n = 816) p value BRS (n = 95) DP-EES (n = 205) p value SD (%)
Lesion profiles
Infarct-related artery 0.057 0.991
LMCA 0 (0) 30 (3.7) 0 (0) 0 (0) 0
LAD 80 (58.8) 407 (49.9) 55 (57.9) 117 (57.1) -
LCx 19 (14.0) 130 (15.9) 14 (14.7) 31 (15.1) -1.51
RCA 37 (27.2) 249 (30.5) 26 (27.4) 57 (27.8) -1.57
ACC/AHA B2/C lesion 121 (89.0) 703 (86.2) 0.449 83 (87.4) 180 (87.8) 1 -3.35
Multi-vessel disease 16 (11.8) 203 (24.9) 0.001 14 (14.7) 36 (17.6) 0.657 -3.8
Procedural characteristics
Transradial approach 116 (85.3) 474 (58.1) <0.001 -6.91
Intravascular image-guided PCI 82 (60.3) 224 (27.5) <0.001 44 (46.3) 80 (39.0) 0.286 3.57
IVUS-guided PCI 32 (23.5) 204 (25.0) 28 (29.5) 61 (29.8) -0.41
OCT-guided PCI 50 (36.8) 20 (2.5) 16 (16.8) 19 (9.3) 3.99
Glycoprotein IIb/IIIa inhibitor 32 (23.5) 107 (13.1) 0.002 19 (20.0) 37 (18.0) 0.807 2.06
Thrombus aspiration 41 (30.1) 110 (13.5) <0.001 23 (24.2) 40 (19.5) 0.437 7.62
Pre-PCI TIMI flow grade 0/1 54 (39.7) 452 (55.4) 0.001 42 (44.2) 88 (42.9) 0.933 5
Post-PCI TIMI flow grade 3 131 (96.3) 773 (94.7) 0.566 93 (97.9) 200 (97.6) 1 2.79
Mean stent/scaffold diameter, mm 3.3 ± 0.3 3.2 ± 0.4 <0.001 3.3 ± 0.3 3.2 ± 0.4 0.474 1.62
Mean stent/scaffold length, mm 21.4 ± 4.5 25.1 ± 7.1 <0.001 22.0 ± 4.5 22.3 ± 6.4 0.656 4.57
Total stent/scaffold number, n 1.2 ± 0.6 1.5 ± 0.8 <0.001 1.3 ± 0.7 1.3 ± 0.6 0.617 -2.47
Values are mean ± SD or n (%).
ACC/AHA, American College of Cardiology/American Heart Association; BRS, bioresorbable scaffolds; DP-EES, durable polymer everolimus-eluting metallic stents;
IVUS, intravascular ultrasound; LAD, Left anterior descending artery; LCx, Left circumflex artery; LMCA, Left main coronary artery OCT, optical coherence
tomography; PCI, percutaneous coronary intervention; RCA, right coronary artery; TIMI, Thrombolysis in Myocardial Infarction
https://doi.org/10.1371/journal.pone.0235673.t002
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significant difference between the groups in the rates of cardiac death, TV-MI, ID-TLR, all
death, all MI, and all revascularization. The 1-year rate of device thrombosis did not differ
between the groups (Table 3).
Independent predictors of DOCE and POCE
A multivariate Cox proportional hazard model revealed independent predictors of the primary
and secondary outcomes (Table 4). Age and Killip class� III were the significant and indepen-
dent predictor of DOCE (HR: 1.03, 95% CI: 1.01–1.06, p = 0.017; HR: 4.90, 95% CI: 2.58–9.31,
p< 0.001, respectively) and POCE (HR: 1.03, 95% CI: 1.01–1.06, p = 0.020; HR: 4.20, 95% CI:
2.17–8.14, p < 0.001).
Fig 2. Cumulative incidence of DOCE and POCE in the crude population (A and B) and propensity-matched population (C and D). BRS, bioresorbable scaffold;
DP-EES, durable-polymer everolimus-eluting metallic stent; DOCE, device-oriented composite endpoint; POCE, patient-oriented composite endpoint.
https://doi.org/10.1371/journal.pone.0235673.g002
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Subgroup analysis
The subgroup analysis for 1-year clinical outcomes showed no significant difference between
BRS and DP-EES implantation across the subgroups (Fig 3). There were no DOCE in young
Table 3. Comparison of 1-year clinical outcomes between the groups.
BRS (n = 136) DP-EES (n = 816) Unadjusted Adjusted PS-adjusted
HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
DOCE 2.2 (3) 4.8 (39) 0.43 (0.13–1.41) 0.163 0.52 (0.16–1.76) 0.295 0.69 (0.18–2.61) 0.585
Cardiac death 0.7 (1) 2.8 (23) 0.26 (0.04–1.92) 0.187 0.34 (0.04–2.55) 0.293 0.89 (0.09–8.95) 0.928
TV-MI 0.7 (1) 1.3 (11) 0.45 (0.06–3.56) 0.449 0.53 (0.06–4.83) 0.573 0.39 (0.04–3.47) 0.397
ID-TLR 1.5 (2) 1.8 (15) 0.70 (0.16–3.10) 0.636 0.87 (0.18–4.17) 0.863 0.62 (0.12–3.14) 0.563
POCE 2.9 (4) 7.8 (64) 0.36 (0.13–0.98) 0.045 0.43 (0.15–1.21) 0.109 0.57 (0.18–1.77) 0.328
All death 0.7 (1) 3.8 (31) 0.19 (0.03–1.41) 0.105 0.27 (0.04–2.03) 0.204 0.41 (0.04–3.87) 0.435
All MI 1.5 (2) 2.6 (21) 0.51 (0.12–2.19) 0.367 0.63 (0.13–2.95) 0.556 0.58 (0.12–2.85) 0.503
All revascularization 2.2 (3) 3.8 (31) 0.53 (0.16–1.75) 0.297 0.54 (0.16–1.87) 0.330 0.73 (0.19–2.81) 0.650
Device thrombosis (definite/probable) 0.7 (1) 0.5 (4) 1.49 (0.16–13.4) 0.719 1.73 (0.15–19.8) 0.658 1.02 (0.09–11.6) 0.989
Values are % (n) unless otherwise indicated.
BRS, bioresorbable scaffolds; CI, confidence interval; DOCE, device-oriented clinical endpoint; DP-EES, durable polymer everolimus-eluting metallic stents; HR, hazard
ratio; ID-TLR, ischemic driven-target lesion revascularization; POCE, patient-oriented clinical endpoint; PS, propensity score; TV-MI, target vessel myocardial
infarction
https://doi.org/10.1371/journal.pone.0235673.t003
Table 4. Independent predictors of clinical outcomes.
Univariate Multivariate
HR (95% CI) P value HR (95% CI) P value
DOCE
BRS implantation 0.43 (0.13–1.4) 0.163
Age� 60 years 1.05 (1.02–1.08) <0.001 1.03 (1.01–1.06) 0.017
STEMI 1.61 (0.86–3.03) 0.139
Killip class� III 5.55 (2.94–10.49) <0.001 4.90 (2.58–9.31) <0.001
HTN 1.20 (0.65–2.20) 0.557
LVEF < 50% 1.35 (0.73–2.47) 0.338
eGFR < 60 mL/min/1.73 m2 3.02 (1.62–5.64) 0.001 1.77 (0.89–3.51) 0.101
Image-guided PCI 0.73 (0.37–1.46) 0.376
Multivessel PCI 0.93 (0.45–1.96) 0.856
POCE
BRS implantation 0.36 (0.13–0.98) 0.045 0.65 (0.19–2.17) 0.483
Age� 60 years 1.04 (1.02–1.06) <0.001 1.03 (1.01–1.06) 0.020
STEMI 1.67 (1.01–2.75) 0.044 1.56 (0.83–2.96) 0.170
Killip class� III 4.47 (2.66–7.48) <0.001 4.20 (2.17–8.14) <0.001
HTN 1.35 (0.84–2.18) 0.213
LVEF < 50% 1.53 (0.95–2.47) 0.078
eGFR < 60 mL/min/1.73 m2 1.92 (1.13–3.26) 0.016 1.73 (0.87–3.45) 0.118
Image-guided PCI 0.8 (0.47–1.36) 0.413
Multivessel PCI 1.04 (0.59–1.82) 0.891
BRS, bioresorbable scaffolds; CI, confidence interval; DOCE, device-oriented clinical endpoint; eGFR: estimated glomerular filtration rate; HR, hazard ratio; HTN,
hypertension; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention; POCE, patient-oriented clinical endpoint; STEMI, ST-segment
elevation myocardial infarction.
https://doi.org/10.1371/journal.pone.0235673.t004
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age (< 60 years), non-ST-elevation myocardial infarction (NSTEMI), image-guided PCI, large
device diameter (� 3.5 mm), and short device length (< 23 mm) groups
Discussion
In the present study, we compared the 1-year clinical outcomes between BRS and DP-EES
treatment in patients with AMI using a nationwide, multicenter, registry data. The main find-
ings of our study were as follows (Fig 4): 1) there were no differences in the incidence of
DOCE, POCE, or device thrombosis between the BRS and DP-EES groups; 2) compared with
DP-EES, BRS was implanted in younger patients with low risk profiles including lower inci-
dence of MVD, no cardiogenic shock, and no left main disease; and 3) in the BRS group, intra-
vascular image-guided PCI, especially, OCT-guided BRS implantation, was performed more
often than in the DP-EES group.
AMI, acute myocardial infarction; BRS, bioresorbable scaffold; CAG, coronary angiography;
CD, cardiac death; DOCE, device-oriented composite endpoint; DP-EES, durable-polymer
everolimus-eluting metallic stent; FU, follow-up; IVUS, intravascular ultrasound; LAD, left
anterior descending artery; MLA, minimal lumen area; MSA, minimal scaffold area; NSTEMI,
non-ST-elevation myocardial infarction; OCT, optical coherence tomography; POCE, patient-
oriented composite endpoint; PCI, percutaneous coronary intervention; ST, stent thrombosis.
Fig 3. Exploratory subgroup analysis for DOCE. DOCE, device-oriented composite endpoint; NSTEMI, non-ST-elevation myocardial infarction; PCI, percutaneous
coronary intervention; STEMI, ST-elevation myocardial infarction.
https://doi.org/10.1371/journal.pone.0235673.g003
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The previous two studies that compared BRS with DP-EES in the setting of AMI have
reported no differences in clinical outcomes between the BRS and DP-EES groups [12,16]. The
first randomized control trial regarding bioresorbable vascular scaffolds in patients with
STEMI demonstrated comparably low prevalence of DOCE and definite device thrombosis at
6 months between the BRS and DP-EES groups [12]. In the propensity-score matched study,
the BRS and DP-EES groups showed similar rates of 1-year DOCE and device thrombosis
[16]. However, compared with the present study in which patients were enrolled from March
2016 to October 2017, these two trials enrolled only patients with STEMI, and the study popu-
lation was enrolled in the early phase of BRS use (December 2012 to September 2014).
Recently, the ISAR-Absorb MI (Intracoronary Scaffold Assessment a Randomized evaluation
of Absorb in Myocardial Infarction), a prospective randomized trial comparing clinical out-
comes after BRS and DP-EES in patients with AMI, reported comparable 1-year clinical events
between the two groups (DOCE: 7.0% [BRS] vs. 6.7% [DP-EES]; POCE; 15.1% [BRS] vs. 14.6%
[DP-EES]; device thrombosis: 1.7% [BRS] vs. 2.3% [DP-EES], respectively) [13]. The present
study of patients not enrolled in a randomized trial also showed no significant differences in
the risk of 1-year DOCE and device thrombosis between the groups. Compared with the
ISAR-Absorb MI, however, the BRS group in this study had a relatively lower incidence of
clinical events (DOCE: 2.2% vs. 7.0%; POCE: 2.9% vs. 15.1%; device thrombosis: 0.7% vs.
Fig 4. Clinical outcomes of BRS in the setting of AMI and an example of successful OCT-guided BRS implantation in a patient with AMI. (A) The current study
showed “real-world” characteristics in patients undergoing BRS implantation and clinical outcomes of BRS and DP-EES were comparable. Angiography in 52-year old
woman presenting with NSTEMI (troponin-I = 35.4 ng/mL) showed significant stenosis in the LAD (B, arrowhead). A 3.0 × 28 mm BRS was deployed after pre-dilation
with a 3.0 × 15 mm compliance balloon, and post-dilation was achieved with a 3.5 × 12 mm non-compliance balloon at 18 atmosphere (C, white circles indicating radio-
opaque markers of BRS). On post-PCI OCT, longitudinal (D) and cross-sectional views (F) showed good scaffold apposition, with good embedment of scaffolds and an
MSA of 5.92 mm2. One-year follow-up angiography (H) shows the patient with implanted BRS and follow-up OCT (E and G) demonstrated that the scaffolds were well
encapsulated by the neointimal tissue.
https://doi.org/10.1371/journal.pone.0235673.g004
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1.7%, respectively [present study vs. ISAR-Absorb MI]). These differences could be explained
by different characteristics of patients in this study. First, the mean age of enrolled patients was
lower in this study than in other AMI-BRS studies [12,13,16]. Patients enrolled in this study
were more than 10 years younger than the average Korean patients with AMI [17]. Young
patients have less calcified plaque and diffuse atherosclerosis in the coronary lesion. Moreover,
the most common plaque morphology in young patients is soft fibroatheroma [18].
Fibroatheroma enables proper embedment and less protrusion of the scaffolds into the lumen,
which could produce better clinical outcomes [19,20]. Therefore, such patients might be ideal
candidates for BRS implantation, and their inclusion in this study may have resulted in a low
prevalence of adverse outcomes. Second, MVD is significantly associated with increased
adverse prognosis [21,22]. Although 40% of patients from the BRS group had MVD in the
ISAR-Absorb MI trial, the prevalence of MVD was about 12% in this study. Moreover, there
was no left main disease as an infarct-related artery in the BRS group. Regarding device pro-
files, shorter device length and fewer implanted devices were observed in the BRS group than
in the DP-EES group, which might represent that lesions have less complexity in the BRS
group. Thus, less severe angiographic lesion characteristics in patients receiving BRS could
account for the good prognosis in the present study.
Interestingly, 60% of patients receiving BRS underwent intravascular image-guided proce-
dures; in particular, OCT-guided PCI was performed in 36.8% of patients in the BRS group
compared with only 2.3% of patients in the DP-EES group. Considering the annual trends of
OCT-guided PCI in Korean patients with AMI, the rate of OCT-guided PCI was high in the
BRS group in this study [23]. The superior resolution (10 μm) of OCT mitigates device failure
by adequate lesion preparation, appropriate choice of diameter and length of BRS, and full
expansion of BRS (Fig 4) [24]. Therefore, intravascular image-guided PCI may have been help-
ful for BRS optimization to prevent adverse clinical events including device thrombosis.
In our subgroup analysis for 1-year clinical outcomes, patients aged older than 60 years,
those presenting with STEMI, or those underwent device implantation by angiography guid-
ance showed similar clinical outcomes in both groups. Interestingly, our study showed no
adverse events at 1 year in patients aged less than 60 years, NSTEMI patients, and patients who
had image-guided PCI in the BRS group. However, meta-analysis demonstrated that BRS had
worse clinical outcomes including device thrombosis, at the 2-year follow-up [10]. Thus,
2-year follow-up coronary angiography or coronary computed tomography angiography
might be considered to detect device failure, especially in patients older than 60 years, STEMI
patients, and patients underwent angiography-guided PCI, although there were no guidelines
of follow-up for patients with BRS implantation. Regarding the subgroup analysis of BRS pro-
files, there was no DOCE in patients receiving large diameter (� 3.5 mm) or short length
(< 23 mm) of BRS. In other words, the effect of BRS for anatomically complex lesions in prior
BRS clinical studies [10,25]. In the previous report, the scaffold design (i.e. thicker strut with
relatively lower radial strength versus metallic stent) was considered as one of the reasons.
Thus, the innovation of material design with reduced strut thickness maintaining radial
strength is desired for the next generation BRS.
There were several limitations in the present study. First, this study has an inherent limita-
tion owing to observational data and small study population, despite the use of a large multi-
center registry. Compared with DP-EES, BRS was implanted in younger patients with simpler
lesions, as the selection of the device used in this study was left to the discretion of the opera-
tors. Further, patients with cardiogenic shock were excluded from this study as no patient in
the BRS group was in a state of cardiogenic shock. As a result, only 136 patients underwent
PCI with BRS, and this small sample size limits the value of careful statistical analysis, includ-
ing propensity-score matching adjustment. Second, we could not evaluate BRS-specific
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protocols, the so-called Pre-dilation, Sizing, Post-dilation (PSP) strategy, which has been sig-
nificantly associated with reduced rates of device failure [26]. Since the PSP strategy was first
introduced by a group of European experts in May 2015, multicenter registry data demon-
strated the effectiveness of the PSP strategy to reduce scaffold thrombosis in March 2016
[27,28]. Therefore, operators may have applied the PSP strategy to most patients in this study,
as patients were enrolled between March 2016 and October 2017. Third, although the plaque
characteristics of young patients and a high proportion of intravascular image-guided PCI pro-
cedures may have led to better clinical outcomes in this study, a detailed analysis of intravascu-
lar images including IVUS and OCT was not performed. Despite these limitations, our study
showed “real-world” data regarding BRS in the setting of AMI and helped determine patients
for whom BRS implantation is suitable.
Conclusions
The implantation of BRS and DP-EES showed similar 1-year efficacy and safety profiles in the
setting of AMI when intravascular image-guided BRS implantation, especially OCT, is per-
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